Fri, Aug 1, 2014, 9:44 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Senesco Technologies Inc. Message Board

  • investora2z investora2z Nov 11, 2013 12:18 PM Flag

    SA articles

    The stock has been in the news recently. A couple of Articles on seekingalpha have expressed positive opinion about the future prospects of the company. Chairman Harlan Waksal's faith in the company is one of the reasons for analyst confidence. He had purchased the company's stock at $26/share in 2012, and has personally secured a $3 million credit line for the company. This investment indicates that he is confident about the future prospects of the company's development stage drug candidate SNS01T. He has a successful track record, and his opinion needs to be given due consideration. Waksal is the co-founder of Imclone, which he had sold to Eli Lilly (LLY) for $6.8 billion. Another director, Christopher Forbes, had also acquired the company's stocks at the same price. Insider purchases signal their optimism about the future. Results in preclinical trials, and cohort 1 & 2 (multiple-myeloma patients) were encouraging. Cohort 2 results were declared in June, and cohort 3 results are expected in a few weeks. The cohort 3 results may lead to a positive reaction if the results are good. The market may begin to value the stock at much higher levels. SNS01T has use in other indications like inflammation and ischemia. Senesco owns numerous patents related to its drug candidate, with applications in agriculture (increasing crop yield), programming of cell death etc. However, the drug candidate has two to three years to go before it receives FDA approval. The trials will require funding from time to time to take the research forward. There is intense competition in the field, though the size of the market also provides a huge opportunity. Like many development stage biotech companies, the risks of investment are relatively high, but the reward is also likely to be commensurate. As mentioned in one SA article, Cohort 3 results could be the near term catalyst.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • All of this is good, and if we do not get some favorable results from cohort 3, then I think we will be in trouble and be forced to close up shop. Even if they "save" the company with additional financing, the cost to current shareholders will be too dilutive to WANT to continue without the promise that results are going to be positive.

      • 1 Reply to csuf70
      • It wont mean we have to close up shop...if nothing happened in cohort 3, there will be a sell off (but how much lower than 10 million can it go). With horrible cohort 3, expect the next round of financings to dilute everyone one significantly.

        Update on my SA article: They got back to me with a bunch of question. Mostly they want references quoted in the article (which is going to take me a long time to find the exact papers) and they want me to write more on other fundamental parts of the company, not just the science. (Which is odd, given I note right in the introduction that the article is being written as a supplementary to other SA articles, but wanted to focus on the science).

        As time is limited this week, I may not get to compete this until next weekend. (sorry).

        Anyone have technical writing experience? When I have to reference a paper/ source, can I get away with putting "Park et al, 1981" or do I have to quote the exact paper published by them, usually done by adding an appendix? (I have seen it done both ways in various papers)

    • History can not gurantee future success. JT spent his entire life to profess factor 5a, there is no reason for this company traded in such miserable valuation. You need to ask the question whether BOD and management did a good job in safeguarding shareholders' interest. Are they recognizing massive share dilution is harmful for the company and depreciations of their intrinsic values? If Harlan could take his personal assets to secure $2 million LOC, why can't Les, Joe and BOD? Are they all not confident on JT's work.

2.02-0.03(-1.46%)Aug 1 3:20 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.